Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Vanderbilt University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Wonder Drake, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT02024555
First received: December 26, 2013
Last updated: August 15, 2014
Last verified: August 2014

December 26, 2013
August 15, 2014
March 2014
March 2017   (final data collection date for primary outcome measure)
Determine the effect of CLEAR therapy versus placebo on the change in percent predicted absolute forced vital capacity (FVC) in participants with pulmonary sarcoidosis, comparing baseline with performance after completion of 16 weeks of therapy. [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT02024555 on ClinicalTrials.gov Archive Site
  • Radiographic improvement in sarcoidosis lung disease by frontal chest x-ray . [ Time Frame: Baseline and 16 weeks ] [ Designated as safety issue: No ]
  • Change in 6 minute walk distance, oxygen saturation and level of dyspnea [ Time Frame: Baseline, 4, 8 and 16 weeks ] [ Designated as safety issue: No ]
    Outcome measure if a composite
  • Change in the Saint George's Respiratory Questionnaire (SGRQ; King's Sarcoidosis Questionnaire (KSQ) for the assessment of health status; The Fatigue Assessment Scale (FAS). [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
    Outcome measure if a composite
  • Safety profile of regimen as evidenced by adverse events and abnormal lab values, tolerability and toxicity of the treatment regimen including comparison of reported adverse events and abnormal laboratory values compared to placebo. [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: Yes ]
  • Change in FEV1 [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Failure of standard Therapy [ Time Frame: Baseline, 4, 8, and 16 weeks ] [ Designated as safety issue: No ]
    We will assess how many subjects in either arm need escalation of their standard regimen (ie increase in prednisone) during the 16 weeks.
  • Radiographic improvement in sarcoidosis lung disease by frontal chest x-ray . [ Time Frame: Baseline and 16 weeks ] [ Designated as safety issue: No ]
  • Change in 6 minute walk distance, oxygen saturation and level of dyspnea [ Time Frame: Baseline, 4, 8 and 16 weeks ] [ Designated as safety issue: No ]
  • Change in the Saint George's Respiratory Questionnaire (SGRQ; King's Sarcoidosis Questionnaire (KSQ) for the assessment of health status; The Fatigue Assessment Scale (FAS). [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Safety profile of regimen as evidenced by adverse events and abnormal lab values, tolerability and toxicity of the treatment regimen including comparison of reported adverse events and abnormal laboratory values compared to placebo. [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: Yes ]
  • Change in FEV1 [ Time Frame: Baseline, 4, 8, 16 and 24 weeks ] [ Designated as safety issue: No ]
  • Failure of standard Therapy [ Time Frame: Baseline, 4, 8, and 16 weeks ] [ Designated as safety issue: No ]
    We will assess how many subjects in either arm need escalation of their standard regimen (ie increase in prednisone) during the 16 weeks.
Not Provided
Not Provided
 
Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial

The primary purpose of this study is to investigate the efficacy and safety of oral antimycobacterial therapy in patients with confirmed progressive pulmonary sarcoidosis. We suspect that the CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants.

Primary Objective: To assess the efficacy and safety of oral CLEAR therapy in patients with confirmed progressive pulmonary sarcoidosis.

Hypothesis: The CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants by augmenting T cell responses through the normalization of p56Lck expression and IL-2 production.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Sarcoidosis; Antimycobacterial Therapy;
  • Drug: Levofloxacin
    Other Name: Levaquin
  • Drug: Ethambutol
  • Drug: Azithromycin
    Other Name: Z-pack
  • Drug: Rifampin
    Other Name: Rifadin, Rimactane
  • Drug: Placebo
    This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
  • Active Comparator: Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin
    Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
    Interventions:
    • Drug: Levofloxacin
    • Drug: Ethambutol
    • Drug: Azithromycin
    • Drug: Rifampin
  • Placebo Comparator: Placebo

    Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.

    The pill count will be the same as the comparator regimen.

    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
128
May 2017
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, as well as biopsy demonstrating granulomas, and no alternative for the cause of the granulomas, such as tuberculosis for at least one year prior to randomization. Tuberculosis must be ruled out by negative histology and culture.
  • Diagnosis of pulmonary sarcoidosis was made at least 1 year prior to consent date.
  • Evidence of disease progression as defined by at least two of the following four criteria:

    1. Decline of absolute percent predicted of FVC (FVC>45% and <=90% of predicted value) or DLCO of at least 5% on serial measurements (DLCO range >35%, if measured);
    2. Radiographic progression in chest imaging on side by side comparison;
    3. Change in dyspnea score, as measured by Transition Dyspnea Index (TDI);
    4. Progression of pulmonary sarcoidosis necessitating an increase in anti-sarcoidosis therapy.
  • Positive peripheral immune responses to ESAT-6 as a biomarker of response to CLEAR regimen.
  • Possess evidence of parenchymal or nodal disease on chest radiograph.

Exclusion Criteria:

  • • Inability to obtain consent

    • Age less than 18 years of age
    • If female, participant is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion: condoms, sponge, foams, jellies, diaphragm, or intrauterine device or a vasectomized sole partner. Note: Oral contraceptive pills are not effective birth control when taking rifampin or rifabutin. Females of childbearing potential must have a negative urine pregnancy test at screening visit
    • End-stage fibrotic pulmonary disease
    • Significant underlying liver disease
    • Poor venous access for obtaining blood samples
    • History of active tuberculosis, close contact with a person with active tuberculosis within the 6 months prior to the screening visit or has a positive PPD.
    • Significant disorder, other than sarcoidosis, that would complicate the treatment evaluation, such as respiratory, cardiac, neurologic, musculoskeletal or seizure disorders
    • Use of an investigational drug within 30 days prior to screening or within 5 half-lives of the agent, whichever is longer.
    • Currently receiving >40mg prednisone.
    • ALT or AST ≥5 times upper limit of normal (ULN)
    • Leukopenia, as defined by WBC <3.0 cells/mm3 or absolute neutrophil count <1000 mm3
    • Breast feeding.
    • Color perception impairment as defined by the inability to differentiate colors per personal history or history of optic neuritis from any cause, including from sarcoidosis.
    • Family or personal history of long QT interval
    • Most recent nuclear medicine scan or echocardiogram (if done), demonstrating cardiac ejection fraction <35%
    • If patient is on immunomodulators, they must be on regimen for ≥3-month period and on a stable dose for ≥ 4 weeks.
    • Participant has persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline. Minocycline and doxycycline are not considered antibiotics when used to treat sarcoidosis.
    • Any significant finding in the patient's medical history or physical or psychiatric exam prior to or after randomization that, in the opinion of the investigator, would affect patient safety or compliance or ability to deliver the study drug according to protocol.
    • On medications that interacts with the antibiotics of the CLEAR regimen (Listed in Appendix A)
    • History of or receiving treatment for pulmonary hypertension.
Both
18 Years and older
No
Contact: Wonder Drake, MD 615-322-2035 wonder.drake@vanderbilt.edu
United States
 
NCT02024555
R01 HL117074, R01HL117074-01
Yes
Wonder Drake, Vanderbilt University
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Wonder Drake, MD Vanderbilt University School of Medicine
Vanderbilt University
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP